Apoptosis is a morphologically distinct form of programmed cell death that plays a major role in cancer treatments. This cellular suicide program is known to be regulated by many dierent signals from both intracellular and extracellular stimuli. Here we report that p53 suppressed expression of the cellular FLICE-inhibitory protein (FLIP) that potentially blocks apoptotic signaling in human colon cancer cell lines expressing mutated and wild-type p53. In contrast, the expression of the death receptor KILLER/DR5 (TRAIL-R2) had no eect on FLIP expression, although exogenous p53 is known to induce KILLER/DR5 expression. In line with these observations, FLIP-negative cancer cells were sensitive to both p53-and KILLER/DR5-mediated apoptosis, whereas cells containing high levels of FLIP underwent apoptotic cell death when triggered by ectopic p53 expression but not by KILLER/DR5 expression. Treating the cells with a speci®c inhibitor of the proteasome inhibited the decrease of FLIP by p53, suggesting that p53 enhances the degradation of FLIP via a ubiquitinproteasome pathway. Thus, the data indicate that p53-mediated downregulation of FLIP may explain the potent sensitization of human cancer cells to the apoptotic suicide program induced by wild-type p53 gene transfer. Oncogene (2001) 20, 5225 ± 5231.
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The tumor suppressor p53 gene is the most commonly mutated gene in a variety of human malignancies and has been shown to be a key link between nuclear DNA damage and the complex cellular responses leading to either cell-cycle arrest or apoptotic cell death. It is now widely accepted that apoptosis is a gene-directed process and associated with several messenger systems that regulate this process either positively or negatively. We previously reported that overexpression of the wild-type p53 (wt-p53) gene by recombinant, replication-de®cient viral vectors induced apoptosis in a variety of human cancer cells diering in p53 status (Kagawa et al., 1997; Fukazawa et al., 1999) . Numerous other studies have shown that p53 mediates its eects by modulating the transcription of a number of cellular target genes (Levine, 1997) . Elucidating the molecular mechanism of p53-mediated apoptosis would provide new insights into the mode of action of conventional DNA-damaging cancer therapies including chemotherapeutic agents and ionizing radiation, as well as the development of novel cancer gene therapies that use the wt-p53 gene.
Triggering the apoptotic pathway requires the crosslinking of ligands such as tumor necrosis factor (TNF), Fas ligand (Fas-L), and TNF-related apoptosis-inducing ligand (TRAIL) to corresponding receptors that contain a death domain (DD) (Ashkenazi and Dixit, 1998 ). The receptors' DD then interacts with the DD of the adapter protein Fas-associated death domain protein (FADD), resulting in proteolytic activation of FADD-like interleukin-1b converting enzyme (FLICE)/caspase-8 (Chinnaiyan et al., 1995) . This releases active FLICE into the cytosol and triggers a cascade of caspases, which are cysteine proteases that play an essential role in apoptotic signaling pathways (Muzio et al., 1996; Medema et al., 1997) . The FLICEinhibitory protein (FLIP), a recently identi®ed intracellular protein that interrupts apoptotic signaling by interacting with a FADD, FLICE/caspase-8, and caspase-10, is structurally similar to FLICE and contains FADD-binding domain (Irmler et al., 1997; Kataoka et al., 1998; Scadi et al., 1999) . Its activesite cysteine, however, is substituted by a tyrosine residue, thus blocking the activity of de®ned caspases. Together, these observations suggest that the levels of intracellular FLIP may determine the sensitivity of tumor cells to apoptosis triggered by a variety of stimuli such as p53, Fas-L, and TRAIL.
We previously reported the p53-mediated upregulation of Fas as well as Fas-L in human cancer cells (Owen-Schaub et al., 1995; Fukazawa et al., 1999) . In addition, the KILLER/DR5 gene has recently been identi®ed as a novel downstream eector of p53 and shown to induce apoptosis in a ligand-independent manner when overexpressed (Wu and el-Diery, 1997; Schneider et al., 1997; Sheikh et al., 1998; Wu et al., 1999) . These ®ndings have led us to investigate the interaction between p53 or KILLER/DR5 and FLIP in human cancer cells. Here, we show that human cancer cell apoptosis induced by p53, but not by KILLER/ DR5, was associated with the downregulation of cellular FLIP expression and that loss of FLIP during the apoptotic process was a result of its enhanced degradation. Using a speci®c inhibitor of the proteasome, we also demonstrate that p53-induced FLIP protein degradation was mediated by the ubiquitinproteasome pathway. Together, these results reveal a novel mechanism by which the wt-p53 can induce apoptosis in human cancer cells.
A replication-de®cient adenovirus vector carrying a wt-p53 gene under the control of the cytomegalovirus (CMV) promoter (Ad5CMVp53) was generated to achieve ecient gene transfer into human cancer cells (Kagawa et al., 1997; Fukazawa et al., 1999) . Monolayer cultures of p53-de®cient H1299 human non-small cell lung cancer (NSCLC) cells, mutant p53-expressing DLD-1 human colorectal cancer cells, and wt-p53-expressing LoVo human colorectal cancer cells were infected with either control dl312 adenovirus or Ad5CMVp53 at a multiplicity of infection (MOI: plaque-forming units [PFU]/cell) of 30. Western blot analysis performed 36 h after infection revealed the increased expression of exogenous p53 as well as endogenous KILLER/DR5 in H1299, DLD-1, and LoVo cells transduced with Ad5CMVp53, as previously reported (data not shown).
To speci®cally express the KILLER/DR5 gene in human cancer cells, we utilized the technique of conditional activation via Cre-loxP mediated recombination (Niwa et al., 1991; Kanegae et al., 1996) . A plasmid, pCALNL-KILLER/DR5, was constructed in which a stuer, composed of the neo gene and polyadenylation signal, and¯anked by a pair of loxP sites, was interposed between the CAG promoter and the KILLER/DR5 cDNA. As the reporter expression unit is expected to initially express the neo gene but not the KILLER/DR5 gene because of the termination of the mRNA sequence within the stuer, the neoresistant clones were selected following transfection of H1299, DLD-1, and LoVo cells. The resultant clones, H1299/DR5, DLD-1/DR5, and LoVo/DR5, were expected to express the KILLER/DR5 gene via the Cre-mediated excisional deletion of the stuer when a sucient amount of Cre recombinase was expressed by Cre-producing recombinant adenovirus (AxCANCre) infection. The increased KILLER/DR5 expression was readily detected by Western blot analysis 48 h after AxCANCre infection at 30 MOI (Figure 1a ). Densitometric quanti®cation of KILLER/DR5 protein levels by dividing the actin signal revealed that AxCANCre infection caused 1.8-, 4.8-, and 1.3-fold increase of KILLER/DR5 expression in H1299/DR5, DLD-1/ DR5, and LoVo/DR5 cells, respectively.
A cell proliferation assay was performed to determine whether wt-p53 or KILLER/DR5 expression was sucient to induce apoptosis in vitro. H1299/DR5, DLD-1/DR5, and LoVo/DR5 cells were inoculated in 24-well plates for 24 h before viral infection. Then, cells were either mock-infected with culture medium or infected with Ad5CMVp53, AxCANCre, or dl312 at 5 or 20 MOI. Cells that remained attached as monolayers were assessed daily for viability by measuring trypan blue uptake. Both Ad5CMVp53 and AxCANCre infection induced rapid cell death in H1299/ DR5 cells even at 5 MOI; AxCANCre infection, however, showed a less profound cytotoxicity against DLD-1/DR5 and LoVo/DR5 cells, although these cell lines were killed well by Ad5CMVp53 infection ( Figure  1b ). This in turn suggests that DLD-1 and LoVo cells were more resistant to KILLER/DR5-mediated cell death. The infection with dl312 had no signi®cant eects on the growth of the three cell lines.
To further study the mechanism of p53-or KILL-ER/DR5-mediated cytotoxicity, we determined the cellcycle distribution by¯ow-cytometric analysis. H1299/ DR5, DLD-1/DR5, and LoVo/DR5 cells were infected with Ad5CMVp53 or AxCANCre at 30 MOI, harvested at 36 h postinfection, and then assayed for DNA content by propidium iodine staining. Whereas mock-and dl312-infected cells showed no speci®c pattern of cell-cycle distribution, three cell lines infected with Ad5CMVp53 exhibited a DNA content less than in the diploid G0/G1 peak, indicating apoptosis-speci®c nuclear fragmentation. However, after AxCANCre-mediated KILLER/DR5 expression, an apoptosis-speci®c sub-G0/G1 peak was observed in H1299/DR5 cells, while DLD-1/DR5 and LoVo/DR5 cell lines showed no signi®cant apoptotic fractions ( Figure 1c ). In addition, after infection with Ad5CMVp53 (30 MOI), all three cell types displayed the hallmarks of apoptosis, i.e.; highly condensed and partially fragmented nuclei, as determined by Hoechst staining and¯uorescence microscopy; after AxCANCre infection, however, apoptosis was detected only in H1299/DR5 cells and not in DLD-1/DR5 and LoVo/ DR5 cells (Figure 1d ). Although introduction of the wt-p53 transgene induced endogenous KILLER/DR5 expression (Wu and el-Deiry, 1997; Sheikh et al., 1998) , the absence of apoptosis following p53-independent KILLER/DR5 expression alone suggests that, in addition to p53-dependent regulation of KILLER/ DR5 gene expression that activates the downstream caspase cascade, the machinery for sensitizing cells to the apoptotic suicide program, which can be directly triggered by p53, appears to be essential for apoptosis in DLD-1 and LoVo cell lines.
Since the resistance of tumor cells frequently correlates with the levels of FLIP (Irmler et al., 1997) , we anticipated that FLIP might be expressed in DLD-1 and LoVo cells, leading to their resistance to KILLER/DR5-induced apoptosis. Indeed, both cell lines expressed detectable levels of FLIP mRNA as shown by reverse transcription-polymerase chain reaction (RT ± PCR) analysis; H1299 cells, however, did not express FLIP mRNA (Figure 2a) . These results raised the possibility that the absence of FLIP expression may render H1299 cells susceptible to KILLER/DR5-mediated apoptosis. Unlike the introduction of KILLER/DR5, introduction of the wt-p53 gene induced a marked apoptotic cell death in DLD-1 and LoVo cells despite the presence of cellular FLIP, thus suggesting the possibility that p53 activation may aect the expression of FLIP. Recently, a decrease in FLIP levels was reported in oxidized low density Figure 1 (a) Conditional expression of the KILLER/DR5 gene by the Cre-loxP system. The human NSCLC cell line H1299, which carries homozygously deleted p53, the human colon carcinoma cell lines DLD-1 and LoVo, which carry the homozygously mutated p53 gene and the wt-p53 gene, respectively. Human KILLER/DR5 cDNA was kindly provided by Dr Hideo Yagita (Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan). The entire KILLER/DR5-coding fragment was subcloned into a pCLNL5 vector to generate pCALNL5-KILLER/DR5. H1299, DLD-1, and LoVo cell lines were transfected with the pCALNL5-KILLER/DR5 plasmid by using LIPOFECT ACE reagent (GIBCO ± BRL). An adenoviral vector containing Cre cDNA (AxCANCre ) was provided by RIKEN Gene Bank (Tsukuba, Japan). The recombinant adenovirus AxCANCre eciently produces a Cre recombinase under the control of the CAG promoter. Stably transfected clones H1299/DR5, DLD-1/DR5, and LoVo/DR5 were infected with either an E1A-deleted control adenovirus vector dl312 or AxCANCre at 30 MOI, and collected 48 h after infection. Cells were then lysed in SDS solubilization buer (62.5 mM Tris-HCl, pH 6.8, containing 10% glycerol, 5% bmercaptoethanol, and 2% SDS) (Sigma, St. Louis, MO, USA). Equal amounts of proteins (20 ± 60 mg) were boiled for 5 min and electrophoresed under reducing conditions on 12.5% (w/v) polyacrylamide gels. Proteins were then electrophoretically transferred to Hybond polyvinylidence di¯uoride (PVDF) transfer membranes (Amersham, Arlington Heights, IL, USA) incubated ®rst with primary rabbit antibodies against KILLER/DR5 (Millennium Biotechnology, CA, USA), and then incubated with a peroxidaselinked secondary antibody. An ECL chemiluminescent Western blotting system (Amersham, Japan) was used to detect secondary probes. (Sata and Walsh, 1998) as well as the activation-induced apoptosis of peripheral T cells (Kataoka et al., 1998) . Because p53 is a sequence-speci®c transcription factor that transactivates its downstream eector genes (Levine, 1997) , one may therefore speculate that p53 can alter the stability of FLIP mRNA and, thus, that the eect of wt-p53 may be transcriptional. We therefore performed a semiquantitative RT ± PCR assay of DLD-1 and LoVo cells after Ad5CMVp53 infection to determine whether the wt-p53 gene transfer could speci®cally aect FLIP expression at the transcriptional levels. As shown in Figure 2b , the amount of the FLIP transcripts was stable for at least 24 h after Ad5CMVp53 infection at 30 MOI in both DLD-1 and LoVo cell lines.
To further study the regulation of FLIP protein expression by wt-p53 gene transfer, we performed Western blot analysis. Such analysis revealed that treatment with Ad5CMVp53 at 30 MOI markedly downregulated expression of the 55-kDa FLIP protein as early as 12 h after infection in DLD-1 cells and 24 h after infection in LoVo cells (Figure 2c ). The observed eect of Ad5CMVp53 was speci®c because we failed to detect any modulation of FLIP protein expression by a control dl312 infection in both cell lines. Signal intensity of FLIP protein was determined densitometrically and normalized against those of actin proteins present in the corresponding lane. Ad5CMVp53 infection resulted in 4.5-and 2.2-fold decrease of FLIP protein levels in DLD-1 and LoVo cells, respectively, 24 h after transduction. In contrast to the induction of p53, AxCANCre-mediated KILLER/DR5 expression resulted in slightly increased levels of FLIP protein in both DLD-1 and LoVo cell lines (Figure 2d ). This dierential regulation of antiapoptotic FLIP may explain why p53 is a more potent inducer of apoptosis than KILLER/DR5. In addition, these results indicate that decreased levels of FLIP are sucient to make DLD-1 and LoVo cells susceptible to apoptosis.
The preceding results indicated that the downregulation of FLIP protein expression after Ad5CMVp53 infection was due to accelerated degradation rather than decreased synthesis of FLIP. Since the degradation of most intracellular proteins is catalyzed by the nonlysosomal ubiquitin-proteasome, we decided to investigate whether proteasomes are involved in the decrease of FLIP by p53 by examining the eect of the Streptomyces metabolite lactacystin, a highly speci®c proteasome inhibitor. DLD-1 and LoVo cells were pretreated with 5 mM lactacystin for 2 h and then transduced with Ad5CMVp53 at 30 MOI for 24 h in the presence of lactacystin. Western blot analysis showed that the lactacystin inhibited the wt-p53-mediated downregulation of FLIP and increased the amount of FLIP through metabolic stabilization of FLIP in both cell lines (Figure 3a) , thus indicating that the wt-p53 gene transfer accelerated the degradation of Figure 2 Eect of wt-p53 gene transfer on FLIP mRNA and protein expression. (a) Detection of FLIP mRNA expression by RT ± PCR analysis. Total cellular RNA was prepared from cells using RNAzol (Cinna/BioTecx, Friendswood, TX, USA) in a single-step phenol-extraction method and used as templates. Reverse transcription was performed at 228C for 10 min and then 428C for 20 min using 1.0 mg of RNA per reaction to ensure that the amount of ampli®ed DNA was proportional to that of speci®c mRNA in the original sample. PCR was performed with speci®c primers in volumes of 50 ml, using a PCR kit according to the manufacturer's protocol (Perkin-Elmer/Cetus, Norwalk, CT, USA). The following speci®c primers were used: for FLIP, FLIP-S (5'-CTC GGC CAA TTT GCC TGTAT-3') and FLIP-AS (5'-GGC AGA AAC TCT GCT GTT CC-3'). The primers for b-actin were b-actin-S (5-TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA-3') and b-actin-AS (5'-CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG-3'). The ampli®cation reaction involved denaturation at 928C for 1 min, annealing at 588C for 1 min, and extension at 728C for 1 min using a thermal cycler (Perkin-Elmer, Foster City, CA, USA). FLIP through the proteasome pathway. Treatment with lactacystin alone showed no apparent eect on the levels of FLIP protein in DLD-1 and LoVo cells (data not shown). These results were con®rmed by the fact that another proteasome inhibitor, MG132 (10 mM), inhibited the decrease in FLIP expression caused by Ad5CMVp53 infection (data not shown). Since ubiquitination is known to target cellular proteins for degradation by the proteasome pathway, we next examined whether the binding of ubiquitin to FLIP as its substrate would increase following wt-p53 gene transfer. Cell extracts were obtained from parental cells and from cells infected with either Ad5CMVp53 or dl312 at 30 MOI, and then immunoprecipitated by incubation with anti-FLIP antibody. Analysis of the immunoprecipitate by Western blotting revealed an 2.5-to 3.5-fold increase in ubiquitin bound to FLIP after Ad5CMVp53 infection (Figure 3b ). Immunoreactivity assays of FLIP showed that equal amounts of proteins were loaded in all lanes. Together, these results indicated that wt-p53 gene transfer could activate the proteasome-dependent proteolysis of FLIP by increasing the covalent attachment of ubiquitin to FLIP, thus leading to the sensitization of human cancer cells to apoptosis.
For ubiquitin to attach to its target protein, the ubiquitin-activating enzyme (E1), the ubiquitin-conjugating enzyme (E2), and the E3 ubiquitin-protein ligases are necessary (Schener et al., 1995) . The degradation of p53 protein in normal as well as tumor cells is known to be mediated by the ubiquitinproteasome system (Shkedy et al., 1994) . MDM2 oncoprotein, which functions as a ubiquitin ligase E3, inhibits p53 activity by targeting p53 for degradation via the proteasome (Honda and Yasuda, 1999) . The fact that p53 itself is a positive regulator of MDM2 transcription supports the hypothesis that wt-p53 gene transfer upregulates MDM2 expression, which may in turn activate the ubiquitination of p53 as well as FLIP and lead to the downregulation of both proteins. A further study to clarify the molecular mechanism is currently under way.
We next examined whether decreased FLIP expression could be accompanied by the activation of proapoptotic mediators such as FLICE/caspase-8, caspase-10, and caspase-3. As shown in Figure 3c , Western blot analysis demonstrated that infection with 30 MOI of Ad5CMVp53 caused 2-, 1.8-, and 3-fold reduction of procaspase-8, procaspase-10, and procaspase-3 protein levels, respectively, in DLD-1 cells, suggesting the activation of caspase cascades by p53 overexpression. In contrast, control dl312 infection had no eect on expression of these caspases.
Finally, to examine the functional signi®cance of FLIP downregulation for the sensitization of human cancer cells to p53-mediated apoptosis, we tested whether ectopic expression of FLIP could protect against apoptosis induced by wt-p53 gene transfer. LoVo cells were transiently transfected with various concentrations of a FLIP expression plasmid ( Figure  4a ) and then infected with Ad5CMVp53 at 30 MOI. The apoptotic cell death induced by wt-p53 gene transfer was partially, but signi®cantly, reduced by coexpression of FLIP in a dose-dependent manner (Figure 4b ). In addition, the stable transfection of the FLIP expression vector prevented DLD-1 and LoVo Whole cell extracts (150 mg) were immunoprecipitated by incubation with 20 mg rabbit antibody against FLIP for 1 h at 48C, followed by incubation with 20 ml protein A/G plus Agarose (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 2 h at 48C. The beads were washed, boiled, and subjected to 12.5% (w/v) polyacrylamide gel electrophoresis. The separated proteins were analysed by Western blot with primary mouse antibody against ubiquitin (Millennium Biotechnology). Blots were also probed with anti-FLIP antibody to con®rm equal loading of samples. (c) Cleavage and activation of caspase-8, caspase-10, and caspase-3 in p53-induced apoptosis of DLD-1 cells. Cell extracts were obtained from DLD-1 cells mock-infected or infected with either dl312 or Ad5CMVp53 at 30 MOI and then analysed on Western blots using anti-caspase 8, anti-caspase-10, anti-caspase-3 (Santa Cruz Biotechnologies), or actin cells from undergoing p53-mediated apoptosis (data not shown).
The success of any anticancer therapy is determined by the eective activation of apoptosis in tumor cells in response to the genotoxic stimuli. Consequently, since the tumor suppressor p53 gene plays an important role in DNA damage-induced apoptosis, the identi®cation of the critical molecular determinants of p53-dependent apoptosis would provide further insights into the development of an apoptosis-based treatment for human cancer. Previous studies have demonstrated that, depending on cell type, p53-induced apoptosis either requires transcriptional activation or occurs without new RNA and protein synthesis (Levine, 1997) . Although a number of apoptosis-related genes that are transcriptionally regulated by p53 have been identi®ed, the transcription-independent downstream pathway of p53 remains largely unclear. We found that wt-p53 gene transfer downregulated antiapoptotic FLIP protein expression in a transcription-independent manner, by activating the ubiquitin-proteasome pathway. Our data therefore suggest that FLIP levels may play a role in determining human cancer cell sensitivity to p53-induced apoptosis.
Since, as we have previously reported, p53 can activate the expression of Fas (Owen-Schaub et al., 1995) as well as Fas ligand (Fas-L) (Fukazawa et al., 1999) in human cancer cells and since the absence of FLIP increases the susceptibility of cells to Fasmediated apoptosis, it may be that p53-induced downregulation of FLIP and upregulation of Fas/ Fas-L cooperate to push cells towards apoptosis. Our ®nding that ectopic FLIP expression could not completely block p53-mediated apoptosis, even though the inhibition was signi®cant and concentration dependent, suggests that multiple pathways may regulate the susceptibility of cancer cells to apoptosis triggered by p53. In fact, it has already been reported that p53-induced apoptosis is associated with the transport of Fas to the cell surface from the Golgi complex (Bennett et al., 1998) . In addition, we have found that p53 activation decreases in NF-kB activity by inhibiting the nuclear translocation of the NF-kB RelA/p65 subunit (Shao et al., 2000) . The downregulation of nuclear expression of NF-kB is a plausible mechanism for apoptosis induced by wt-p53 gene transfer since NF-kB activation generally appears to inhibit apoptosis. Moreover, these scenarios may be analogous to the downregulation of FLIP protein levels since the mechanism appears to be independent of transcription.
In conclusion, our data provide evidence that p53 can mediate apoptosis through the downregulation of antiapoptotic FLIP expression. It is also worth noting here that p53 regulates FLIP protein levels via the ubiquitin-proteasome system in a transcription-independent manner. This novel function of p53 in the pathway of apoptosis may have important implications for the development of p53-based tumor therapeutics either alone or in combination with other therapeutic strategies. 
